143 related articles for article (PubMed ID: 2901077)
1. Transdermal scopolamine-induced psychosis.
Ziskind AA
Postgrad Med; 1988 Sep; 84(3):73-6. PubMed ID: 2901077
[TBL] [Abstract][Full Text] [Related]
2. [An unusual case of psychosis caused by long-term administration of a scopolamine membrane patch. Paranoid hallucinogenic and delusional symptoms].
Rubner O; Kummerhoff PW; Haase H
Nervenarzt; 1997 Jan; 68(1):77-9. PubMed ID: 9132625
[TBL] [Abstract][Full Text] [Related]
3. [Scopolamine plaster caused hallucination. Toxic psychosis in a 10-year-old boy caused by an agent against motion sickness].
Björk M; Wettergren B
Lakartidningen; 1995 Feb; 92(7):638. PubMed ID: 7861858
[No Abstract] [Full Text] [Related]
4. A comparison of motion sickness remedies in severe sea conditions.
Gahlinger PM
Wilderness Environ Med; 2000; 11(2):136-7. PubMed ID: 10921365
[No Abstract] [Full Text] [Related]
5. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
[TBL] [Abstract][Full Text] [Related]
6. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
Nachum Z; Shupak A; Gordon CR
Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
[TBL] [Abstract][Full Text] [Related]
7. Transdermal scopolamine intoxication in a child.
Klein BL; Ashenburg CA; Reed MD
Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169
[No Abstract] [Full Text] [Related]
8. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
Levy GD; Rapaport MH
Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
[TBL] [Abstract][Full Text] [Related]
9. Scopolamine withdrawal syndrome.
Saxena K; Saxena S
Postgrad Med; 1990 Jan; 87(1):63-6. PubMed ID: 2296571
[TBL] [Abstract][Full Text] [Related]
10. Transderm Scop patches for prevention of motion sickness.
Johnson P; Hansen D; Matarazzo D; Petterson L; Swisher C; Trappolini A
N Engl J Med; 1984 Aug; 311(7):468-9. PubMed ID: 6749195
[No Abstract] [Full Text] [Related]
11. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
Patel PN; Ezzo DC
Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
[TBL] [Abstract][Full Text] [Related]
12. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma.
Hamill MB; Suelflow JA; Smith JA
Ann Ophthalmol; 1983 Nov; 15(11):1011-2. PubMed ID: 6651138
[TBL] [Abstract][Full Text] [Related]
13. Side effects of transdermal scopolamine.
Wilkinson JA
J Emerg Med; 1987; 5(5):389-92. PubMed ID: 3668203
[TBL] [Abstract][Full Text] [Related]
14. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
[TBL] [Abstract][Full Text] [Related]
15. Transdermal scopolamine in motion sickness.
Cronin CM; Sallan SE; Wolfe L
Pharmacotherapy; 1982; 2(1):29-31. PubMed ID: 6927209
[TBL] [Abstract][Full Text] [Related]
16. More on Transderm Scop patches.
N Engl J Med; 1984 Nov; 311(21):1377-8. PubMed ID: 6493292
[No Abstract] [Full Text] [Related]
17. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
Attias J; Gordon C; Ribak J; Binah O; Rolnick A
Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
[TBL] [Abstract][Full Text] [Related]
19. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
Wang E
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
[TBL] [Abstract][Full Text] [Related]
20. Transdermal scopolamine in the prevention of motion sickness at sea.
Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
